TapewireFind a company

person · Reporting owner

Ring Christine

Disclosed activity across 1 company

Tapewire entity
1157
SEC CIK
0001817199

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nurix Therapeutics, Inc.NRIX · Entity 1156Chief Legal OfficerOctober 02, 2026October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nurix Therapeutics, Inc.

Report date October 02, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,110 Ending reported balance After 2026-10-02 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12Direct111,251 Reported balance After 2026-10-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 30, 2025 Filed Jan 31, 2025 00:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 291 $20.33 $5,914.75
Disclosure

SEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,538

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 2,929 $19.81 $58,014.12
Disclosure

SEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,829

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 00:53 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 02, 2025 Filed Jan 2, 2025 22:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,986

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
January 02, 2025 Filed Jan 2, 2025 22:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,760 $19.50 $112,294.66
Disclosure

SEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,084

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.91 and the highest price at which shares were sold was $19.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
January 02, 2025 Filed Jan 2, 2025 22:28 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
December 02, 2024 Filed Dec 2, 2024 23:00 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,746

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
December 02, 2024 Filed Dec 2, 2024 23:00 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,760 $21.73 $125,155.01
Disclosure

SEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,084

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.48 and the highest price at which shares were sold was $22.09. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
December 02, 2024 Filed Dec 2, 2024 23:00 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
November 04, 2024 Filed Nov 4, 2024 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 3,290 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,389

Underlying: Common Stock · 3,290 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024.

Read SEC document
November 04, 2024 Filed Nov 4, 2024 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,290 $25.00 $82,250.00
Disclosure

SEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,084

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
November 04, 2024 Filed Nov 4, 2024 22:48 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,290 $9.57 $31,485.30
Disclosure

SEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
November 01, 2024 Filed Nov 1, 2024 21:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,506

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
November 01, 2024 Filed Nov 1, 2024 21:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,760 $24.28 $139,866.62
Disclosure

SEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,084

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.99 and the highest price at which shares were sold was $24.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
November 01, 2024 Filed Nov 1, 2024 21:57 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 7

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 6

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,621

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 4,182 $24.31 $101,643.51
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,084

F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2024 Filed Oct 31, 2024 00:30 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 1,924 $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 14, 2024 Filed Oct 15, 2024 13:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 3,290 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · derivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,679

Underlying: Common Stock · 3,290 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024.

Read SEC document
October 14, 2024 Filed Oct 15, 2024 13:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 3,290 $25.00 $82,250.00
Disclosure

SEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,592

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 14, 2024 Filed Oct 15, 2024 13:16 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,290 $9.57 $31,485.30
Disclosure

SEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,882

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
October 01, 2024 Filed Oct 1, 2024 23:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,266

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
October 01, 2024 Filed Oct 1, 2024 23:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 300 $22.81 $6,843.00
Disclosure

SEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,592

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $22.76 and the highest price at which shares were sold was $22.85. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 01, 2024 Filed Oct 1, 2024 23:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,460 $22.19 $121,174.33
Disclosure

SEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,892

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.75 and the highest price at which shares were sold was $22.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
October 01, 2024 Filed Oct 1, 2024 23:36 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 3,290 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · derivative · entry 6

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,969

Underlying: Common Stock · 3,290 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F5 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,026

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 200 $25.62 $5,124.00
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,592

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.50 and the highest price at which shares were sold was $25.74. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 8,850 $24.93 $220,611.92
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,792

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $24.46 and the highest price at which shares were sold was $25.41. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 3,290 $9.57 $31,485.30
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,642

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
September 03, 2024 Filed Sep 3, 2024 21:33 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
August 26, 2024 Filed Aug 26, 2024 22:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,407 $0.00 Strike: $9.57 $0.00
Disclosure

SEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,259

Underlying: Common Stock · 5,407 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024.

Read SEC document
August 26, 2024 Filed Aug 26, 2024 22:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 4,463 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,537

Underlying: Common Stock · 4,463 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · derivative.exercise_date: The stock option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
August 26, 2024 Filed Aug 26, 2024 22:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 9,870 $25.01 $246,842.78
Disclosure

SEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,592

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.00 and the highest price at which shares were sold was $25.14. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 26, 2024 Filed Aug 26, 2024 22:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,407 $9.57 $51,744.99
Disclosure

SEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
August 26, 2024 Filed Aug 26, 2024 22:23 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 4,463 $1.86 $8,301.18
Disclosure

SEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
August 01, 2024 Filed Aug 1, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 5,760 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · derivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,786

Underlying: Common Stock · 5,760 shares

Expires 2029-09-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

Read SEC document
August 01, 2024 Filed Aug 1, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 300 $22.18 $6,654.99
Disclosure

SEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 3

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,592

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $22.05 and the highest price at which shares were sold was $22.45. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 01, 2024 Filed Aug 1, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 5,460 $21.39 $116,803.60
Disclosure

SEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 2

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,892

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.94 and the highest price at which shares were sold was $21.75. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document
August 01, 2024 Filed Aug 1, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionCommon Stock 5,760 $1.86 $10,713.60
Disclosure

SEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 1

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,352

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 3,750 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 7

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 3,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 2,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 6

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 Exercise / conversionRestricted Stock Units · Derivative 1,924 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 5

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,545

Underlying: Common Stock · 1,924 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date.

Read SEC document
July 30, 2024 Filed Jul 30, 2024 23:06 UTC Nurix Therapeutics, Inc. NRIX · Entity 1156 SaleCommon Stock 2,920 $20.67 $60,349.68
Disclosure

SEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 4

Ring Christine · CIK 0001817199 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,592

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.